PET Scan
Enhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MoreSignificance of 18F-fluorodeoxyglucose PET/computed tomography in the initial staging of malignant peritoneal mesothelioma
Nuclear Medicine Communications 2025 May 6 [Link] Hui Zhang, Lifang Pang, Jun Hou, Beilei Li, Yiqiu Zhang Abstract Objective: This study was aimed at evaluating the significance of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) in the staging and differentiation of malignant peritoneal mesothelioma (MPeM). Materials and methods: We retrospectively analyzed clinical and imaging data of 21…
Read MorePotential advantage of magnetic resonance imaging in detecting thoracic wall infiltration in pleural mesothelioma: A retrospective single-center analysis
JTCVS Open 2024 October 22 [Link] Isabel Barreto, Sabine Franckenberg, Thomas Frauenfelder, Isabelle Opitz, Olivia Lauk Abstract Objectives: Thoracic wall infiltration in pleural mesothelioma determines the extent of resection and can be an important prognostic factor. Currently, standardized imaging for restaging after neoadjuvant systemic therapy comprises contrast-enhanced computed tomography or positron emission tomography. Additional thoracic…
Read MoreIncidental Diagnosis of Malignant Peritoneal Mesothelioma During Liver Transplantation Surgery: A Case Report
The American Journal of Case Reports 2024 July 17 [Link] Spogmai Khan, Adnan Malik, Shahbaz Qureshi, Babak Cohen, Abdul Nadir Abstract BACKGROUND Malignant peritoneal mesothelioma (MPM) is a rare, lethal tumor of serous membranes. The most common factor reported in association with MPM is asbestos exposure, while viral infections, genetic predisposition, paraneoplastic syndrome, and altered…
Read MoreMajor pathological response obtained after neoadjuvant chemotherapy combined with dual immunotherapy for malignant pleural mesothelioma: a case report
Translational Lung Cancer Research 2024 June 30 [Link] Yuchen Zhang, Guangyin Zhao, Chen Xu, Jie Gu, Di Ge Abstract Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with high morbidity and mortality. A combination of systemic therapy and surgery may be a promising modality for the treatment of MPM, but evidence-based medicine is…
Read MoreFibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Journal of Nuclear Medicine 2024 July 3 [Link] Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel Wiesweg, Clemens Aigner, Till Plönes, Kaid Darwiche, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Rainer Hamacher, Wilfried E E Eberhardt, Martin Schuler, Ken Herrmann, Wolfgang P Fendler, Hubertus Hautzel…
Read MoreComparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma
Oncotarget 2024 June 20 [Link] Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, Koichiro Yamakado Abstract Objectives: Results for malignant pleural mesothelioma (MPM) patients following first-line treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST (imPERCIST), shown by [18F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), and…
Read MoreThe Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach: How Much Staging Do We Really Need?
Cancers 2024 May 17 [Link] Arberit Hyseni, Jan Viehof, Jan Hockmann, Martin Metzenmacher, Wilfried Eberhardt, Ken Herrmann, Hubertus Hautzel, Clemens Aigner, Till Plönes Abstract Pleural mesothelioma (PM) is a very aggressive malignancy with a poor prognosis. Most patients receive systemic treatment only; however, some patients may benefit from multimodality treatment. A precise staging of patients…
Read MoreExtensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT
World Journal of Nuclear Medicine 2023 December 4 [Link] Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2…
Read MoreCase Report: Early diagnosis and bevacizumab-based chemotherapy for primary pericardial mesothelioma: a case with occupational asbestos exposure history
Frontiers in Cardiovascular Medicine 2023 November 20 [Link] Daniel Wang, Yung Hsuan Wang, Sung Chao Chu Abstract Background: Primary pericardial mesothelioma (PPM) is an exceedingly rare malignant cancer and has a poor prognosis, which has been partly attributed to its frequently delayed diagnosis due to its nonspecific syndromes, its similar presentation to benign pericardial diseases,…
Read More